Evidence map›Paper›PMID 39484753›Full record

ReviewCurrent neuropharmacology2025

A New Augmentation Strategy against Depression Combining SSRIs and the N-terminal Fragment of Galanin (1-15).

Antonio Flores-Burgess, Carmelo Millon, Noelia Cantero-Garcia, Juan Pedro Pineda-Gomez, Marta Flores-Gomez, Zaida Diaz-Cabiale

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Antonio Flores-BurgessDepartamento de Fisiología, Facultad de Medicina, Universidad de Málaga, Campus de Teatinos s/n. 29080 Málaga, Spain.
Carmelo MillonDepartamento de Fisiología, Facultad de Medicina, Universidad de Málaga, Campus de Teatinos s/n. 29080 Málaga, Spain.
Noelia Cantero-GarciaDepartamento de Fisiología, Facultad de Medicina, Universidad de Málaga, Campus de Teatinos s/n. 29080 Málaga, Spain.
Juan Pedro Pineda-GomezDepartamento de Fisiología, Facultad de Medicina, Universidad de Málaga, Campus de Teatinos s/n. 29080 Málaga, Spain.
Marta Flores-GomezDepartamento de Fisiología, Facultad de Medicina, Universidad de Málaga, Campus de Teatinos s/n. 29080 Málaga, Spain.
Zaida Diaz-CabialeDepartamento de Fisiología, Facultad de Medicina, Universidad de Málaga, Campus de Teatinos s/n. 29080 Málaga, Spain.

Funding

Spanish Ministry of Health EXP2022/008766Spanish Ministry of Science PID2020-114392RB-100, PDC2021-121566-100University of Málaga B1-2021_07, B4-2023-02
6 · The paper itself

Abstract

Depression is one of the most disabling mental disorders, with the second highest social burden; its prevalence has grown by more than 27% in recent years, affecting 246 million in 2021. Despite the wide range of antidepressants available, more than 50% of patients show treatment-resistant depression. In this review, we summarized the progress in developing a new augmentation strategy based on combining the N-terminal fragment of Galanin (1-15) and SSRI-type antidepressants in animal models.

Indexed as

Antidepressive AgentsDepressionGalaninPeptide FragmentsSelective Serotonin Reuptake InhibitorsAnimalsDrug Therapy, CombinationHumansAntidepressive AgentsGalaninPeptide FragmentsSelective Serotonin Reuptake Inhibitorsanimal modelsantidepressants.augmentation therapyDepressionGAL(1-15)SSRIs

Identifiers

PMID39484753
PMCPMC11808584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.